First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Xeris Biopharma: the setup is constructive — Gvoke prescription volume trends and market share gains versus Lilly's Baqsimi and Amphastar's generic glucagon…
★ Analysts see FY2026 revenue reaching $386M — +32.3% growth in a single year.
Why Revenue Could Explode
1Gvoke prescription volume trends and market share gains versus Lilly's Baqsimi and Amphastar's generic glucagon emergency kits
2Baqsimi integration success post-acquisition including revenue synergies, formulary access retention, and cross-selling effectiveness
3Recorlev commercial uptake in Cushing's syndrome market (estimated 20,000 US patients) and potential label expansions
4Path to profitability milestones including quarterly operating expense trends, EBITDA breakeven timing, and cash runway visibility
5Pipeline development updates for XP-8121 (continuous subcutaneous hydrocortisone infusion for adrenal insufficiency) and other formulation technologies
6Payer coverage decisions and formulary positioning for key products affecting reimbursement rates and patient access
growth - The 81.7% one-year return and 23.9% revenue growth attract growth investors focused on commercial-stage biotech companies scaling…
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples…
Watch on earnings: Gvoke total prescription volume (TRx) trends from IQVIA weekly prescription data, Quarterly revenue per product and gross-to-net percentage reflecting payer rebate trends, Adjusted EBITDA and operating cash flow progression toward breakeven.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $386M to $473M as gvoke prescription volume trends and market share gains versus lilly's baqsimi and amphastar's generic glucagon.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.